Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study
Ningjing Lin, Mingzhi Zhang, Hai Bai, Hui Liu, Jie Cui, Xiaoyan Ke, Huilai Zhang, Lihong Liu, Dongmei Yan, Yongsheng Jiang, Aimin Zang, Junyuan Qi, Li Wang, Zhuogang Liu, Bing Xu, Ying Zhang, Zhihui Zhang, Xielan Zhao, Chunhong Hu, Shenmiao Yang, Hui Zhou, Jinsheng Shi, Zonghong Shao, Ying Xiang, Jiman Zhu, Yuqin Song, Jun Zhu, Ningjing Lin, Mingzhi Zhang, Hai Bai, Hui Liu, Jie Cui, Xiaoyan Ke, Huilai Zhang, Lihong Liu, Dongmei Yan, Yongsheng Jiang, Aimin Zang, Junyuan Qi, Li Wang, Zhuogang Liu, Bing Xu, Ying Zhang, Zhihui Zhang, Xielan Zhao, Chunhong Hu, Shenmiao Yang, Hui Zhou, Jinsheng Shi, Zonghong Shao, Ying Xiang, Jiman Zhu, Yuqin Song, Jun Zhu
Abstract
Background: GLS-010 (zimberelimab) is a novel, fully human, anti-programmed death-1 monoclonal antibody that shows promising efficacy and safety in advanced solid tumors. This trial aimed to evaluate the efficacy and safety of GLS-010 (zimberelimab) in Chinese patients with relapsed or refractory classical Hodgkin lymphoma (r/r-cHL).
Methods: This phase II, single-arm, open-label, multicenter clinical trial was conducted at 24 centers in China and enrolled patients with r/r-cHL after two or more lines of therapy. The patients were administered intravenous GLS-010 (zimberelimab) (240 mg, once every 2 weeks) until progression, death, unacceptable toxicity, or consent withdrawal. The primary end-point was the objective response rate assessed by an independent radiology review committee (IRC). This study was registered (NCT03655483).
Results: Eighty-five patients were enrolled between August 2018 and August 2019. The median follow-up was 15.8 months. Seventy-seven patients (90.6%; 95% confidence interval [CI] 82.3-95.9) had an IRC-assessed objective response. The complete response rate was 32.9% (n = 28). The 12-month progression-free survival and overall survival rates were 78% (95% CI 67.5-85.6) and 99% (95% CI 91.9-99.8), respectively. Treatment-related adverse events (TRAEs) were observed in 92.9% of participants. Grade III or IV TRAEs occurred in 24 (28.2%) of the 85 participants. The most common grade III or IV TRAEs were abnormal hepatic function (5.9%), hyperuricemia (4.7%), decreased neutrophil count (3.5%), and increased weight (3.5%). Only one grade V AE, gastrointestinal infection, occurred.
Conclusions: GLS-010 (zimberelimab) appears to be effective and safe for the treatment of Chinese patients with r/r-cHL. Long-term follow-up is required to confirm these clinical benefits.
Keywords: Hodgkin lymphoma; Monoclonal antibody; PD-1; Response; Treatment response.
Conflict of interest statement
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jiman Zhu: President of Guangzhou Gloria Biosciences Co., Ltd. Other authors declare no conflict of interest.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed